Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

Completed · Not applicable · Has a placebo group

Conditions studied: Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance

In brief

The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.

Key facts

Study ID

NCT01488279

Run by

University of Vermont

People needed

10

Starts

2012-09-01

Expected to finish

2015-12-01

Last updated by the study team

2018-03-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women
• impaired fasting glucose
• We will stratify for weight and age.

You may not qualify if…

• Known Type 2 DM
• Severe disease preventing participation in study
• On chronic steroids for any reason
• Already taking DPP-4 inhibitor

Where it is running

• University of Vermont Clinical Research Center — South Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.